Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential
Lingling Wang, Ying Liang, Chunxia Zhao, Peijun Ma, Shulin Zeng, Dongen Ju et al. · 2025 · 146 citationsRead the paper
Regulatory T cells (Treg cells or Tregs), a subset of CD4⁺ T cells with immunosuppressive properties, are essential for immune homeostasis and self-tolerance. Characterized by their immunosuppressive capabilities and reliance on the transcription factor Foxp3 (Forkhead box protein P3), Tregs employ multiple mechanisms, including cytokine secretion, metabolic control, and cell contact inhibition, to restrain excessive immune activation to prevent autoimmunity while maintaining tissue repair processes. However, dysregulation in their frequency or function-whether deficiency or hyperactivity-is implicated in diverse pathologies, spanning autoimmune disorders, cancer progression, transplant rejection, and emerging associations with neurological and cardiovascular diseases. Thus, Treg-targeted strategies represent a promising approach for restoring immune balance under various conditions. This review synthesizes current knowledge on Treg biology, from their discovery and definition of markers to their new regulatory mechanisms. We further explore the roles of Tregs across diseases, emphasizing their context-dependent therapeutic potential. Strategies to deplete or inhibit Tregs in cancer immunotherapy contrast with approaches to expand or stabilize their function in autoimmunity and transplantation. However, challenges persist, including achieving tissue-specific targeting, ensuring the functional stability of engineered Tregs, and minimizing off-target effects. By integrating mechanistic insights with translational innovations, this review provides a roadmap for advancing Treg-based therapies, ultimately aiming to restore immune equilibrium in a disease-specific manner.
What the full text shows
Working prototype- Ex vivo expanded autologous Tregs were found to be safe for patients with type 1 diabetes. (Human clinical trial (2014))
- Treg depletion or transplantation of in vitro-depleted Treg suspensions suppresses tumor growth. (T cell-deficient mice)
- Deletion of Treg-derived IL-10 and IL-35 in the tumor microenvironment reduces tumor growth. (Tumor microenvironment)
- CD36 deletion in Tregs increases IFN-γ and TNF-α production and reduces tumor infiltration. (Tumors)
- Treg numbers and functionality are notably decreased in patients with untreated multiple sclerosis, active systemic lupus erythematosus, and active Crohn’s disease. (Human patients)
- Setup
- Review of preclinical studies, human clinical trials (GVHD, Crohn's, Type 1 Diabetes), and single-cell RNA sequencing data.
- How
- The paper is a comprehensive review synthesizing existing literature on Treg biology, markers, metabolic pathways, and therapeutic strategies across various diseases.
- Limitations
- Simple infusion of autologous Tregs often fails due to pre-existing functional disorders in patients. · Challenges in achieving tissue-specific targeting and ensuring functional stability of engineered Tregs. · Potential for off-target effects and autoimmune complications during Treg depletion/inhibition.
Summarized by Gemma 4 from the open-access full text · 10 Oct 2026. Read it